Immunotherapy innovation
We are a preclinical immunotherapeutics company focused on developing improved, accessible cancer treatments. Our pipeline features proof-of-concept products for multiple myeloma, adjuvant therapy for colorectal cancer, and the management of systemic lupus erythematosus (SLE).
Our team
Brent Zanke
MD, PhD
Founder and CEO
Brent is a medical oncologist, immunologist, and serial entrepreneur. He has extensive knowledge of drug development and reimbursement, gained through leadership roles in systemic therapy at two major cancer care systems, where he also advanced Myellama’s lead assets in their early stages.
Greg Johnson
Chief Financial Officer
Greg is a biotech and clinical research executive with recognized expertise in strategic planning, program management, and operations. He has extensive international experience in the United States, Canada, Germany, and the United Kingdom. His background spans all aspects of clinical research and drug development, including pre-IND strategy, CMC, toxicology, clinical-stage execution, and the negotiation of licensing agreements with major pharmaceutical partners.
Ken Newport
Board Chair
Ken is part of Canada’s growing life sciences ecosystem with a leadership style focused on innovation, disciplined execution, and strategic collaboration across scientific and commercial domains. As Founder and Chief Executive Officer of CroMedica Inc. he has prioritized innovative approaches in drug delivery and precision therapeutics, working to translate early-stage discoveries into clinical and commercial solutions. Under his leadership, the company has formed partnerships and implemented financing strategies to accelerate product development and broaden its technology platform.
Allisa Visram
MD, MPH, FRCPC
As a hematologist at the Hamilton Health Sciences Center, Allisa improves outcomes for patients with multiple myeloma through immunotherapies, including bispecific antibodies and cellular therapies. She is active in clinical trials evaluating next-generation therapies, real-world treatment outcomes, optimization of sequencing strategies, and management of therapy-related toxicities. Allisa is also engaged in advancing personalized care approaches for patients with plasma cell dyscrasias, including smouldering myeloma and monoclonal gammopathy of undetermined significance (MGUS).
Science and Medicine Advisory Board
As a senior pharmaceutical executive at Johnson & Johnson, Richard contributed to strategy, clinical development, and lifecycle management across a portfolio of therapies for hematologic malignancies. His work has focused particularly on multiple myeloma and related blood cancers, where he has helped develop and position novel therapeutics globally, including monoclonal antibodies and next-generation immunotherapies.
Richard Plante
John Bell
PhD
John is known for his pioneering work in cancer immunotherapy and oncolytic virus research. He is a senior scientist at the Ottawa Hospital Research Institute. His work has contributed to the clinical translation of novel viral therapies and combination immunotherapy strategies, helping position Canada as a global leader in this field.
In addition to his scientific contributions, John has held major leadership roles, including serving as Scientific Director of the Terry Fox Research Institute. There, he oversaw national research programs to accelerate cancer discovery and improve patient outcomes. He has also been involved in multiple biotech ventures and collaborative initiatives bridging academia and industry.
Fund the future of immunotherapy
We are looking for investors to advance our family of products to clinical testing.